Mark Goldsmith
Chief Executive Officer presso REVOLUTION MEDICINES, INC.
Patrimonio netto: 27 M $ in data 31/03/2024
Profilo
Mark A.
Goldsmith founded Cogentus Pharmaceuticals, Inc. in 2006, where he worked as Chairman, President & Chief Executive Officer from 2006 to 2009 and Revolution Medicines, Inc. in 2014, where he is working as Chairman, President & Chief Executive Officer.
Dr. Goldsmith also currently works at Nura Bio, Inc., as Director.
Dr. Goldsmith also formerly worked at Global Blood Therapeutics, Inc., as President, Chief Executive Officer & Director in 2012, Nurix Therapeutics, Inc., as Chairman from 2014 to 2016, Constellation Pharmaceuticals, Inc., as Chairman from 2012 to 2021, Igenica Biotherapeutics, Inc., as Director, The J.
David Gladstone Institutes, as Assistant Director, Genencor International, Inc., as Senior Vice President, Roche Group, as Member, Prospect Venture Partners, as Senior Executive-in-Residence, and Third Rock Ventures LLC, as Partner from 2013 to 2015.
Dr. Goldsmith received his undergraduate degree from Princeton University and doctorate degree from The University of California, San Francisco.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 10/04/2024 | 841 274 ( 0.51% ) | 27 M $ | 31/03/2024 |
Posizioni attive di Mark Goldsmith
| Società | Posizione | Inizio |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Chief Executive Officer | 01/11/2014 |
Nura Bio, Inc.
 Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Director/Board Member | - |
Precedenti posizioni note di Mark Goldsmith
| Società | Posizione | Fine |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Executive Officer | 01/03/2012 |
| NURIX THERAPEUTICS, INC. | Chief Executive Officer | 18/09/2014 |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/01/2015 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Chief Executive Officer | 17/06/2014 |
Cogentus Pharmaceuticals, Inc.
 Cogentus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cogentus Pharmaceuticals, Inc. develops pharmaceutical products. Its investors include The Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital, and Pinnacle Ventures. The company was founded by Mark A. Goldsmith in 2006 and is headquartered in Menlo Park, CA | Chief Executive Officer | 18/12/2009 |
Formazione di Mark Goldsmith
| Princeton University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NURIX THERAPEUTICS, INC. | Health Technology |
| REVOLUTION MEDICINES, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
Cogentus Pharmaceuticals, Inc.
Cogentus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cogentus Pharmaceuticals, Inc. develops pharmaceutical products. Its investors include The Keffi Group, Prospect Venture Partners, Ridgeback Capital, Apothecary Capital, and Pinnacle Ventures. The company was founded by Mark A. Goldsmith in 2006 and is headquartered in Menlo Park, CA | Health Technology |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Prospect Venture Partners
 Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California. | Finance |
The J. David Gladstone Institutes
 The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | Commercial Services |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Mark Goldsmith
